6431 — Kuangli Bio Tech Holdings Co Income Statement

0.000.00%

Last trade - 00:00

Consumer DefensivesAdventurousMicro CapMomentum Trap

Annual income statement for Kuangli Bio Tech Holdings Co, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.

	R2020 December 31st	R2021 December 31st	R2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	87	333	342	293	381
Cost of Revenue
Gross Profit	1.45	90.9	68.7	66.3	68.3
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	136	276	431	416	552
Operating Profit	-48.7	56.8	-88.8	-123	-171
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-41	59.4	-84.5	-124	-182
Provision for Income Taxes
Net Income After Taxes	-41.9	54.6	-70.7	-104	-173
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	-62.9	25.8	-68.7	-104	-173
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	-62.9	25.8	-68.7	-104	-173
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-0.918	0.053	-1.21	-1.72	-2.27
Dividends per Share